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play response data. Analysis by question, category and demographic descriptor was 
performed. Results: 90% of learners were able to apply the content of the training 
within 4 weeks. Learners reported a notable increase in improving animal health 
and production as a result of the training. Most learners (> 90%) view the program 
as a worthwhile investment in their career. Significantly less managers feel the 
same way (< 45%). A ROI calculation result for total percent job improvement due to 
training is 1.7 times the top 25% benchmark. Surprisingly, those with greater than 
10 years tenure find the program to be just as worthwhile or more compared to the 
other tenure groups and the group with the largest number of employees also saw 
the greatest Job Impact from the training. ConClusions: The training provides 
much needed resources for the industry since most learners found it a worthwhile 
investment and the ROI calculation is high. This analysis allows for data driven 
decisions to be made for program adjustment and learner selection.
PIH44
Trends In PaTIenT CenTered researCH In THe PublIsHed lITeraTure
Covington D1, Veley KM2, Williams H3
1PPD, Wilmington, NC, USA, 2PPD, Morrisville, NC, USA, 3PMG Research Inc., Wilmington, NC, 
USA
objeCtives: In a previous study we found a steep increase in the use of the term 
“patient-centered” in the published literature from < 10 articles in the 1960s to > 3000 
in the 2010s. We also noted an increase in the proportion of articles in each decade 
reporting original research (17 vs 90%). The objective of this study was to further 
examine the subset of articles reporting original research. Methods: We searched 
EMBASE for articles written in English between 1950-2013 with ‘patient-centered’ in 
the title or abstract. We selected a random sample of 10 articles within each decade 
and captured data from the title and abstract on the focus of the article (healthcare, 
research, or teaching). We selected those focused on research and extracted additional 
data on the study design, data collection methods, number of cases, comparator 
group, and statistics used. We examined trends in these variables over time using 
tabular and graphical methods. Results: Our search identified 5051 publications, 
of which 2222 reported original research, from 1966-2013. Articles in earlier decades 
tended to report qualitative research (> 55%), whereas articles published since 2010 
used more sophisticated study designs (> 75%). The majority of studies in all decades 
employed descriptive statistics; however multivariate methods were used in 25% 
of studies in the 2010s. The use of a comparator group (16 vs 50%) and the average 
number of subjects (38 vs 687) also increased steadily over time. ConClusions: In 
addition to the increase in original research publications with “patient-centered” 
in the title or abstract over the last 50 years, we observed an increase in scientific 
and methodological rigor among these original research articles. These findings are 
consistent with the rise in personalized-medicine in the healthcare industry today, 
as well as the upsurge in the use of patient-reported outcome data that characterizes 
clinical research today.
PIH45
Can a web-based Tool To faCIlITaTe CommunICaTIon beTween PaTIenT 
and HealTHCare ProvIders ImProve PaTIenT-rePorTed ouTComes?
Cleverley D
Personal Healthcare Information, Pittstown, NJ, USA
objeCtives: Patients with barriers such as normal anxiety around illness, low asser-
tiveness, or cognitive issues may have trouble communicating with their healthcare 
providers (HCP). HCPs are under increasing pressure to see more patients daily. Can 
a web-based training and worksheet help patients have improved outcomes, even in 
the face of these challenges? Methods: US and European patients were trained to 
produce an electronic, printable worksheet that contained the following: a detailed 
description of their primary complaint, including location, duration, and intensity 
according to Likert scale, correlation to activity, quality, and history. The worksheet 
also included a functional impact statement around daily activities of living and 
social activities, a therapy preferences statements and a statement of symptom 
management goals. Results: Of 25 patients, 14 responded to an outcomes survey: 
10/14 (71%) of the respondents were female, with a range of 30-72 years of age 6/14 
(42.9%) consulted 5 or more HCPs and 9/14 (64.3%) had 5 or more healthcare visits 
for their healthcare issue prior to completing the worksheet 9/14 (64.3%) indicated 
they had some miscommunication with their HCP regarding medication A major-
ity of patients had received costly blood tests (81.8%), X-rays (72.7%), and MRI/CATS 
scans (63.6%) for their healthcare issue Most patients (78.6%) used the worksheet to 
have a discussion around a new treatment option they hadn’t previously discussed, 
and almost half 6/14 (42.9%) were able to get a diagnosis for a healthcare issue not 
previously diagnosed using the worksheet; Many [9/14 (64.3%)] said the worksheet 
helped reduce office-visit related anxiety and helped them discuss symptom man-
agement [8/14 (57.2%)]. ConClusions: This simple web-based tool was useful in 
facilitating communication between patients and their HCPs, which led to diagno-
sis, receiving new treatments, and better symptom management, even in patients 
with long-standing healthcare issues, multiple visits, extensive testing, and multiple 
healthcare providers.
PIH46
PaTIenT rePorTed ouTComes: are THey relevanT To u.s. Payers?
Bayliss M1, Hughes TE2
1Optum, Lincoln, RI, USA, 2Optum, Scottsdale, RI, USA
objeCtives: Identify the current and future relevance of Patient Reported 
Outcomes (PROs) among U.S. payers making patient access decisions for pharma-
ceuticals Methods: Double blind, semi-structured telephone interviews with 12 
U.S. payers, including: National and regional commercial payers; Accountable Care 
Organizations; Pharmacy Benefit Managers; Self-insured employers; Actuaries; 
Veterans Affairs; and Department of Defense. Interviews included open-ended 
questioning and structured rating scales where 10= highest and 1= lowest possible 
score per concept. Results: Payers perceive PROs as the, “Consequences of the 
disease and drug as assessed by the patient...” Average rating scale responses were: 
How relevant are PROs? today? = 3.7 in 5 years? = 6.4 Would you like to see more PRO 
evidence? today? = 6.1 in 5 years? = 6.6 Should pharmaceutical companies invest 
more in PROs? today? = 5.6 in 5 years? = 6.3 The sum of the 6 scales (min= 6, max 
= 60) ranged from 12 to 58, highlighting diversity across payers. PRO relevance was 
associated with the duration of enrollment and thus total amount of risk. DoD and 
ACOs reported the highest relevance, National Commercial Health plans the lowest. 
Education was consistently identified as a need to aid interpretation of PRO data to 
support patient access decisions. ConClusions: Payers’ reliance on PRO data will 
increase in the next five years, especially in symptomatic conditions without objec-
tive measures of success. PRO evidence is valued as a unique predictor of clinical 
and economic outcomes and as a key element of performance and quality ratings. 
Respondents showed interest in pharmaceutical companies’ increasing use of PROs 
in clinical trials, creation of real world evidence and supporting PRO education.
PIH47
for Two ComPanIes THe fda Pro GuIdanCe leads To sImIlar buT 
dIfferenT measures: a Case sTudy In PsorIasIs
Mordin M1, Brown TM2, McLeod L2, DeMuro C2, Gnanasakthy A2
1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Research Triangle Park, NC, 
USA
objeCtives: The objective of this research is to evaluate whether the 2009 FDA PRO 
Guidance leads to development of similar measures when followed by different 
researchers in the same disease. Psoriasis was selected as a case study, because 
two companies recently published patient-reported outcome measures to assess 
the severity of psoriasis-related symptoms: the Psoriasis Symptom Inventory (PSI) 
and the Psoriasis Symptom Diary (PSD). Methods: Full-length publications related 
to the development of the PSI and PSD were reviewed. The following information 
regarding the development process and key aspects pertinent to the PRO Guidance 
were extracted and compared: patient population, development steps (literature 
review, involvement of patients during item development), psychometric proper-
ties, content of final measure, recall period, response options, and scoring. The 
authors conducted a qualitative evaluation of the differences between the meas-
ures. Results: Five publications regarding the development of the measures were 
identified (PSI, n = 3; PSD, n = 2). Both measures focus on symptoms of moderate 
to severe psoriasis. Both measures were based on literature reviews, patient input, 
and expert opinion and had similar psychometric properties. Both measures have 
a 24-hour recall period. However, the measures consist of different numbers of 
disease-specific symptoms (PSI = 8; PSD = 6). The PSI consists of 8 items, all of which 
measure symptom severity. The PSD consists of 16 items (bother of symptoms = 8, 
severity of symptoms = 6, skin color = 1, hiding skin = 1). Additionally, the measures 
assess symptoms differently. The PSI uses a 5-point Likert scale, while the PSD uses 
an 11-point numeric rating scale; both measures equate higher scores with greater 
severity. ConClusions: This example demonstrates that when different experts 
develop patient-reported outcome measures to assess identical concepts and to 
align with the FDA PRO Guidance, the result is similar but not identical.
PIH48
swITCHInG In ParT d PresCrIPTIon Plan: Plan swITCHInG versus brand 
name druG swITCHInG
Basu R
Baylor Scott & White Health, Temple, TX, USA
objeCtives: There is a dearth of evidence on factors influencing prescription plan 
switching versus switching from brand name drug to generic one. However, either of 
this switching decision could significantly impact health and wellbeing of Medicare 
beneficiaries. The objective of the present study was to better understand the rela-
tive impacts of individual versus prescription plan level characteristics on both of 
these switching decisions. Methods: Medicare beneficiaries participated in the 
2007 HRS prescription drug survey and 2009 HRS well-being survey and enrolled in 
Medicare part D (stand-alone), HMO, fee-for service or Advantage plans. The study 
sample includes 1298 individuals responded both years surveys. . Random inter-
cept multinomial logistic regression model was estimated. Results: Only 5% of 
sample members switched into different prescription plans in both 2007 and 2009, 
while about 24% individuals switched from brand name drugs to generic product to 
save prescription drug costs. An outcome variable of interest includes 4 categories: 
switched into different part D plan, switch from brand to generic drug, thought about 
switching but did not actually switch and didn’t do anything. The main covariates 
of interest include individual and plan level characteristics. Compared to “didn’t do 
anything” Individuals were more likely to switch to different prescription plan (13%) or 
switched into generic drug from brand name (25%) if they were using higher number 
of prescription medications (p< 0.04). Individuals having plans with good customer 
service was 54% less likely to switch into different part-D plan. Compared to “didn’t 
do anything” individuals were 123% more likely to stay on the same plan being not 
satisfied with the current plan if they experience “inertia” in the plan choice deci-
sion. ConClusions: Unobserved plan level characteristics matter in part-D plan 
switching or drug switching decisions. Consumer inertia and plan’s customer service 
quality appear to be important factors influencing these switching decisions.
PIH49
a ConCePTual framework for TranslaTInG PaTIenT-rePorTed 
ouTComes for ImPlemenTaTIon In ClInICal PraCTICe and QualITy 
ImProvemenT efforTs
Jeswani N, Gaur P, Ganesan N, Mitchell K
Avalere Health, Washington, DC, USA
objeCtives: As healthcare becomes more patient-centered, patient-reported out-
comes (PROs) are assuming a growing role in different aspects of care. Avalere sought 
to define a conceptual framework on the criteria for defining, implementing, and 
translating PROs into valid, reliable measures of performance. Methods: Conducted 
a structured literature review to identify influencers in the translation of PROs, issues 
that impact translation, and relationships between key variables. Results: Various 
A112  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
stakeholders (including researchers, industry, academia, FDA, clinicians, and payers) 
play an important role in translation. Avalere defined four stages in the translation of 
PROs: issue identification, research, clinical practice, and implementation in quality 
and performance measurement. Literature revealed that PROs for research purposes 
must be developed, tested, and evaluated with baseline science standards in mind, 
such as psychometric soundness, rigor, validity, generalizability, and aggregatabil-
ity. PROs used in clinical practice are subject to additional criteria considering the 
science behind practicality, interoperability, and timing/mode of administration. At 
the implementation stage, there is the opportunity to define a particular outcome or 
process of care that can be assessed by a PRO. Once rigorously evaluated for scien-
tific acceptability, feasibility of data collection, and other criteria, PRO measures can 
be implemented in quality reporting or payment programs with established bench-
marks. ConClusions: Stakeholders are still ironing out the “kinks” of the develop-
ment, use, and implementation of PROs. Our conceptual framework for PRO translation 
can provide a starting point for stakeholders interested in applying best practices to 
the routine use of PROs in clinical trials and at the point of care, and as PRO measures 
become more sophisticated, in quality reporting and payment programs.
PIH50
CHoosInG beTween THe PromIs Global and eQ-5d for ComParaTIve 
effeCTIveness researCH: are THey really dIfferenT?
Runge SK, Craig BM
Moffitt Cancer Center, Tampa, FL, USA
objeCtives: To inform the design of comparative effectiveness studies (CER), a 
head-to-head psychometric comparison of the PROMIS Global and EQ-5D instru-
ments is needed. Methods: In 2013, 2289 US adults completed an online survey 
including 10 items from the PROMIS Global and 5 items from the 3 EQ-5D versions 
(EQ-5D-3L, EQ-5D-Y, and EQ-5D-5L) in random order. After testing for unidimen-
sionality between each pair of these 25 items, we conducted 3 separate exploratory 
factor analyses (EFA) between the PROMIS Global and each EQ-5D version. Next, we 
performed an item-response-theory (IRT) analysis for factors shared between the 
2 instruments. Item levels with insufficient responses (n< 40) were collapsed. The 
relative degree of information obtained by each instrument was assessed using an 
unconstrained graded response model. Results: All items were positively cor-
related (0.32 to 0.98). Regardless of EQ-5D version, EFA analyses identified 3 factors 
(eigenvalue > 1): Physical Health (PH), Mental Health (MH), and Quality of Life (QL). 
Each item uniquely loaded to a single factor after rotation. Unlike PH and MH, QL 
included only PROMIS items. At a threshold of 0.5 in standard error, the IRT analy-
ses showed similar PH information function ranges by instrument (-0.2 to 2.8 for 
EQ-5D-5L vs. -0.2 to 2.4 for PROMIS Global). However, the MH information range for 
EQ-5D-5L was substantially narrower than the range for the PROMIS Global (0.3 to 
2.4 vs. -0.8 to 2.8). ConClusions: The PROMIS Global includes 5 items that extend 
the measurement of general health beyond the 2 factors shared with the EQ-5D. 
When comparing the remaining 5 items of the PROMIS Global to the EQ-5D, the 
instruments appear to share information ranges in PH, but the PROMIS Global has 
a broader MH range than the EQ-5D. These similarities and differences are impor-
tant considerations when choosing between the PROMIS Global and EQ-5D for CER.
PIH51
ImPaCT of symPTomaTIC burden amonG women dIaGnosed wITH 
uTerIne fIbroIds on HealTH-relaTed QualITy of lIfe: an assessmenT 
usInG uTerIne fIbroId symPTom and QualITy of lIfe QuesTIonnaIre 
(ufs-Qol)
Soliman AM1, Margolis MK2, Castelli-Haley J1, Coyne KS2
1AbbVie Inc., North Chicago, IL, USA, 2Evidera, Bethesda, MD, USA
objeCtives: Uterine fibroids (UF) are associated with significant reduction in 
health-related quality of life (HRQL). This cross-sectional survey examined the 
impact of UF-related symptoms on HRQL using a disease-specific instrument, the 
UFS-QoL. Methods: An online survey of US women between 18 and 54 years was 
conducted using 3 large respondent panels as a sampling frame. Data collected 
included demographics, UF prevalence, symptoms, HRQL and health-related produc-
tivity. Descriptive statistics were used to examine the impact of symptom presence, 
symptom severity, bothersomeness, and number of UF-related symptoms on multiple 
domains of HRQL. Analyses were weighted to match the population distribution of 
age, education, region, and household income of US female population. Results: 
59,411 (15.5%) of the panel members who were contacted completed the prevalence 
screener; 5,879 met inclusion criteria for survey completion. Of those, 1,397 had UF 
and no hysterectomy. Mean age was 42.8 years; 65% were white; 62% were married 
or in a civil union. Among the most common symptoms experienced in the past 4 
weeks, at least 49% rated each symptom as at least “moderate” severity and > 87% 
rated a symptom as at least “somewhat bothersome”. Mean UFS-QoL subscale scores 
were significantly (p< 0.05) worse among women who reported each UF symptom 
versus women in whom the symptom was absent. In particular, the presence of 
bleeding and also non-bleeding symptoms (pelvic pressure, low back pain, abdominal 
pain, bloating, and fatigue/weariness/anemia) was related to worse UFS-QoL subscale 
scores. Women who rated their UF symptoms as severe had significantly (p< 0.001) 
worse UFS-QoL scores versus women with mild or moderate UF symptoms. In addi-
tion, UFS-QoL subscale scores worsened as the number of UF symptoms experienced 
increased. ConClusions: HRQL among women with UF was significantly impacted 
by UF-related symptoms. A more pronounced impact was observed as the number 
and severity of symptoms increased.
PIH53
Common CHronIC CondITIons, dIsabIlITy and PerCeIved HealTH: 
emPIrICal suPPorT of a ConCePTual model
Alonso J1, Forero C2, Adroher N2, Vilagut G3
1Universitat Pompeu Fabra (UPF), Barcelona, Spain, Barcelona, Spain, 2CIBER Epidemiología y 
Salud Pública (CIBERESP), Barcelona, Spain, 3IMIM-Institut Hospital del Mar d’Investigacions 
Mèdiques, Barcelona, Spain
objeCtives: A predominant Health-Related Quality of Life Model (described by 
Wilson and Cleary in 1995) proposes a sequential relationship from biological and 
physiological variables to perceived health and overall quality of life. We assessed 
the extent to which disability mediates the association between mental and physi-
cal conditions with perceived health. Methods: Data come from the WHO World 
Mental Health (WMH) Surveys carried out in 22 countries worldwide (n = 51,344 
respondents, 72.0% response rate). We assessed 9 common mental disorders with 
the WHO Composite International Diagnostic Interview v3.0 (CIDI), and 10 chronic 
physical with a checklist. Perceived health (PH) in the previous 30 days was assessed 
using a numerical scale (from 0, worst, to 100, best). Disability was assessed using 
a modified WHO Disability Assessment Schedule 2.0 (WHODAS). Path analysis and 
multigroup techniques were used to estimate total effects of physical and mental 
conditions on perceived health PH and their separate direct and indirect (through 
the latent and observed WHODAS dimensions) effects. Results: 12-month preva-
lence was 14.4% for any mental and 51.4% for any physical condition. Disability was 
common and a 31.7% had problems with Role functioning, 11.4% with Mobility and 
8.3% with Stigma. Overall mean Perceived Health (PH) scores was 81. The model 
explained 36% of PH score variance and estimated a significant score decrement 
of 8.5 for individuals with a mental disorder and of -8.2 for those with a physical 
condition. Of those decrements, 73.7% (mental) and 59.0% (physical) were “indirect” 
effects (i.e., mediated by disability). Mediation importance of disability domains dif-
fered by mental and physical conditions. ConClusions: A large proportion of the 
decrement in perceived health associated with common conditions is mediated by 
disability. Disability mediation patterns are different for mental and physical condi-
tions. These data support the validity of the Health-Related Quality of Life Model.
PIH54
HealTH relaTed QualITy of lIfe In PaTIenTs usInG ComPlemenTary 
alTernaTIve medICIne (HomeoPaTHy) In QueTTa, PakIsTan
ul Haq N1, Akram A1, Iqbal Q1, Naseem A1, Mohammd S1, Ahmed N1, Farooqui M2
1University of Balochistan, Quetta, Pakistan, 2Universiti Teknologi MARA (Bertam campus), 
Penang, Malaysia
objeCtives: To evaluate the Health related quality of life among patients using 
complementary Alternative medicine (homeopathy) in Quetta, Pakistan. Methods: 
A cross sectional, descriptive study was undertaken among the patients visiting 
three major homeopathic clinics in Quetta City, Pakistan. Health related quality of 
life was assessed using European Quality of Life scale (EQ-5D). Descriptive analysis 
was used to elaborate patients’ demographic characteristics while inferential sta-
tistics were applied to report the association among study variables. Results: Out 
of 500 questionnaires distributed 486 were received with a response rate of 97.2%. 
Gender distribution was 264 (54.4%) males. Mean age of the study participants was 
34.05 ± 13.0 years with 334 (68.7%) married and 431 (88.7%) having urban residency. 
The mean EQ-5D descriptive score and EQ-VAS score were 0.59 ± 0.22 and 60.19 ±16.9 
respectively. ConClusions: The health related quality of life in patients using 
Homeopathy is slightly low then Health related quality of life of general population 
of Quetta. This study provides baseline assessment for the health status of patients 
using homeopathy and the results could be applied in clinical practice.
PIH55
faCTors ImPaCTInG PersonalIzed medICIne TesT adoPTIon: evaluaTInG 
PaTIenT PreferenCes and wIllInGness To Pay
Canestaro WJ1, Regier DA2, Veenstra DL1, Lavallee D1, Basu A1, Carlson JJ1
1University of Washington, Seattle, WA, USA, 2Canadian Centre for Applied Research in Cancer 
Control (ARCC), British Columbia Cancer Agency, Vancouver, BC, Canada
objeCtives: Personalized medicine tests (PMT) are increasingly available in the 
healthcare marketplace. The diffusion of such technologies is in part a function of 
the collective preferences of patients, providers, and payers. The objective of our study 
was to identify the attributes of PMTs most important to patients and thus likely to 
impact individual decisions and population level adoption. Methods: We used a 
mixed methods study design to identify the attributes of PMTs that impact patient 
decision-making. We recruited patients with and without prior PMT experience to 
participate in focus groups and interviews via flyers, provider contacts, and disease 
support groups. Patients completed an attributes ranking exercise and a payment 
card scenario to estimate willingness-to-pay (WTP) for PMTs. Analysis of transcripts 
was performed using thematic coding, analysis of attribute ranking used a rank-
ordered logit model, and payment card data was conducted using interval regres-
sion. Results: We contacted 32 patients of which 20 ultimately participated (focus 
groups: 14; interviews: 6). Analysis of the attribute rankings indicated that the most 
important attributes were: 1) ability to select the appropriate treatment, 2) benefit to 
family members, and 3) quality of life after testing. The rankings for these character-
istics were all statistically significant. The average willingness-to-pay for a PMT was 
$1,528 (95%CI: $361-2,694). Patients making less than $25K/year had a statistically 
significant lower WTP ($373) compared to the population average. ConClusions: 
Patients showed a strong preference for the ability to select the appropriate treatment 
based on test results as well as the impact of test results on their family and their 
quality of life. Patients were willing to pay more than would typically be required 
in an insured population but less than the full cost of some commonly used PMTs. 
This work will ultimately be used to inform the development of a discrete choice 
experiment.
IndIvIdual’s HealTH – Health Care use & Policy studies
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ImPaCT of PedIaTrIC reGulaTIon on avaIlabIlITy of neonaTe druG 
InformaTIon
Lindberg-Springs S1, Nambiar S1, Seoane-Vazquez E2
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2MCPHS University, 
Boston, MA, USA
